Monash University

University / College


Location: Melbourne / Clayton, Australia (AU) AU

ISNI: 0000000419367857

ROR: https://ror.org/02bfwt286

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (2017) Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, Pan X, et al. Journal article Capacity of the Gaussian Two-Hop Full-Duplex Relay Channel with Self-Interference (2016) Zlatanov N, Sippel E, Jamali V, Schober R Conference contribution, Conference Contribution Capacity of the Two-Hop Relay Channel With Wireless Energy Transfer From Relay to Source and Energy Transmission Cost (2016) Zlatanov N, Wing Kwan Ng D, Schober R Journal article Novel protocol with improved outage probability performance for the fading two-hop half-duplex relay channel (2016) Zlatanov N, Jamali Kooshkghazi V, Wing Kwan Ng D, Schober R Conference contribution Capacity of the two-hop full-duplex relay channel with wireless power transfer from relay to battery-less source (2016) Zlatanov N, Wing Kwan Ng D, Schober R Conference contribution Multi-objective beamforming for energy-efficient SWIPT systems (2016) Leng S, Wing Kwan Ng D, Zlatanov N, Schober R Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial (2016) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 2-YEAR EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, FUTURE 1 (2016) Kavanaugh A, Mease P, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials (2016) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution THE EUROPEAN SOCIAL PREFERENCE MEASUREMENT (ESPM) STUDY: CONCEPTUAL CONSIDERATIONS AND IMPLEMENTATION (2016) Schlander M, Telser H, Holm S, Marshall DA, Nord E, Richardson J, Garattini S, et al. Conference contribution